COVID-19 in vaccinated versus unvaccinated hematologic malignancy patients

Article Oncology

COVID-19 vaccination and breakthrough infections in patients with cancer

A. L. Schmidt et al.

Summary: This study analyzes the clinical features of cancer patients who develop symptomatic COVID-19 after vaccination. It finds that these patients often have comorbidities and can experience severe and even lethal infections. Hematologic malignancy patients are over-represented among the vaccinated cancer patients who develop symptomatic COVID-19. Therefore, while vaccination remains crucial in protecting vulnerable populations, including cancer patients, those who develop breakthrough infections despite full vaccination still face the risk of severe outcomes.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Hematology

Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy

Remy Dulery et al.

Summary: Age >= 70 years, relapsed/refractory lymphoma, and recent administration of anti-CD20 therapy are risk factors for prolonged length of in-hospital stay and death for lymphoma patients hospitalized for Covid-19.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia have a significantly impaired antibody response to the BNT162b2 mRNA COVID-19 vaccine, which is influenced by disease activity and treatment.

BLOOD (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant

Xianding Deng et al.

Summary: A new SARS-CoV-2 variant named B.1.427/B.1.429 was identified in California, with increased transmissibility and carrying three mutations in spike protein, including L452R substitution. The variant emerged in May 2020 and became predominant in sequenced cases from September 2020 to January 2021. In vivo viral shedding was increased and antibody neutralization decreased, calling for further investigation.

CELL (2021)

Add to Collection

Letter Oncology

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies

Lee M. Greenberger et al.

CANCER CELL (2021)

Add to Collection

Article Medicine, General & Internal

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

Mark G. Thompson et al.

Summary: The study demonstrated that COVID-19 mRNA vaccines were highly effective in preventing SARS-CoV-2 infection in real-world conditions, while also attenuating the viral RNA load, febrile symptoms, and illness duration among vaccinated individuals who had breakthrough infections.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment

M. Peeters et al.

Summary: The study found that cancer patients receiving COVID-19 vaccination experienced mostly mild to moderate local and systemic adverse events, with more frequent local adverse events following the booster dose. Additionally, immunized cancer patients had delayed and diminished antibody responses, particularly in those receiving chemotherapy or rituximab treatments.

ESMO OPEN (2021)

Add to Collection

Article Economics

Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2

Manuela Di Fusco et al.

Summary: This study evaluates COVID-19 vaccine breakthrough infections among immunocompromised individuals, showing that breakthrough infections are more common and severe in this population, with a higher hospitalization and mortality rate compared to non-immunocompromised individuals. The findings support the FDA authorization and CDC recommendations for a third vaccine dose to increase protection among immunocompromised individuals.

JOURNAL OF MEDICAL ECONOMICS (2021)

Add to Collection

Article Hematology